Immuno oncology assays market seen rising to $8.9 billion by 2030
The immuno oncology assays market is projected to grow from $4.88 billion in 2025 to $5.52 billion in 2026, with demand fueled by cancer incidence, biomarker-driven diagnostics and immunotherapy research. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region through 2030.
Why it matters: - Immuno oncology assays are becoming central to cancer research and personalized treatment. - Market growth signals rising demand for tools that measure immune response, guide therapy selection and track treatment outcomes. - The market’s expansion reflects broader investment in immunotherapy, biomarker testing and precision oncology.
What happened: - The Business Research Company released its Immuno Oncology Assays Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report values the market at $4.88 billion in 2025 and forecasts $5.52 billion in 2026. - The report projects the market will reach $8.9 billion by 2030. - The report estimates a 13.1% CAGR from 2025 to 2026 and a 12.7% CAGR through 2030. - The report was published Oct. 20, 2026. - The company also offered a free sample of the report and the full market report.
The details: - Immuno-oncology assays are laboratory tests that evaluate the immune system’s activity against cancer. - These assays measure biomarkers, immune cell function, cytokine levels and tumor-related gene expression. - The tests help researchers and clinicians assess immunotherapy effectiveness, monitor outcomes and identify predictive biomarkers. - Market growth is being driven by rising global cancer incidence, higher investment in cancer immunotherapy research, wider use of biomarker-based diagnostics and growing adoption of personalized medicine. - Increased clinical oncology research is also supporting demand. - Demand is rising for advanced immune profiling assays that provide a fuller view of patient immune response. - Precision oncology is gaining ground because it tailors treatment to tumor characteristics. - Novel immunotherapies are expanding the need for companion tests and predictive biomarkers. - Pharmaceutical companies and research institutions are increasing collaborations, which is accelerating assay innovation and adoption. - Multiplex assays are gaining traction because they can analyze multiple biomarkers at once. - Companion diagnostics are becoming more important in immunotherapy development. - Biomarker-based approaches are being used more often in clinical trials. - Advanced assay platforms are drawing interest because they can speed research workflows and improve efficiency. - The report includes market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables.
Between the lines: - The report points to a market shift from broad cancer testing toward more targeted, biomarker-led decision-making. - North America’s lead suggests a mature research base and stronger healthcare infrastructure, while Asia-Pacific’s expected growth signals rising cancer burden and new investment. - The commercial opportunity extends beyond testing volume to platforms that integrate speed, multiplexing and clinical decision support. - CDC data cited in the release underscore the demand side: the United States recorded about 1.85 million new cancer diagnoses in 2022 and 613,349 cancer deaths in 2023. - Tobacco and alcohol use remain important contributors to cancer incidence because they increase exposure to carcinogens and mutation risk.
What’s next: - Asia-Pacific is expected to be the fastest-growing regional market over the forecast period. - Ongoing progress in immunotherapy, companion diagnostics and biomarker-driven trials is likely to keep assay demand elevated. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America and the Middle East and Africa. - The company directs readers to the report and sample request pages for more detail.
The bottom line: - Immuno oncology assays are moving from a niche research tool to a core part of precision cancer care, and the market is set for sustained double-digit growth.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
LATAM Technology Reporter
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.